Using a controlled study design, we have demonstrated the promising potential of the combined regime (liraglutide+PYY3-36) as an alternative to RYGB in the treatment of obesity, as shown in a previous publication [31] and as summarized in the introduction. Here, PYY3 is linked to obesity due to melanocortin 4 receptor deficiency.